Table 2.
Patient distribution according to body composition
| SAT index | SM index | |||||
|---|---|---|---|---|---|---|
| Low | High | P value | Low | High | P value | |
| Number | 441 | 440 | 441 | 440 | ||
| SAT index, (Median) | – | – | 5.93 (0.22–32.42) | 8.69 (0.21–88.09) | <0.001b | |
| Mean (±SD), cm2/m2 | – | – | 7.90 ± 6.61 | 11.99 ± 11.93 | ||
| SM index, (Median) | 44.88 (14.78–89.03) | 51.72 (8.03–89.06) | <0.001b | – | – | <0.001b |
| Mean (±SD), cm2/m2 | 46.31 ± 13.91 | 51.60 ± 14.43 | – | – | ||
| BMI (kg/m2), Median | 21.43 (13.87–28.26) | 25.61 (17.24–37.30) | <0.001b | 21.93 (13.87–31.78) | 25.12 (16.87–37.30) | <0.001b |
| Mean (±SD), cm2/m2 | 21.48 ± 2.52 | 25.97 ± 3.07 | 22.12 ± 3.02 | .25.33 ± 3.40 | ||
| Underweight, n (%) | 55 (12.5%) | 2 (0.5%) | <0.001a | 54 (12.2%) | 3 (0.7%) | <0.001a |
| Normal, n (%) | 345 (78.2%) | 178 (40.5%) | 314 (71.2%) | 209 (47.5%) | ||
| Overweight, n (%) | 41 (9.3%) | 216 (49.1%) | 69 (15.6%) | 188 (42.7%) | ||
| Obese, n (%) | 0 (0%) | 44 (10.0%) | 4 (0.9%) | 40 (9.1%) | ||
| EQD2 Gy (Median) | 72 (64–74) | 72 (64–74) | 0.456b | 72 (64–74) | 72 (64–74) | 0.997b |
| Mean (±SD) | 71.3 ± 1.45 | 71.2 ± 1.56 | 71.31 ± 1.59 | 71.21 ± 1.42 | ||
| Treatment days (Median) | 52 (44–69) | 52 (39–70) | 0.956b | 52 (44–70) | 52 (39–70) | 0.063b |
| Mean (±SD) | 53.49 ± 4.47 | 53.47 ± 4.73 | 53.44 ± 4.59 | 53.52 ± 4.62 | ||
| Age (years) Median | 49.5 (19.3–85.56) | 52.1 (27–85.2) | <0.001b | 51.4 (19.3–85.2) | 50.572 (21.7–85.6) | 0.135b |
| Mean (±SD) | 49.5 ± 10.8 | 53.35 ± 11.6 | 52.0 ± 12.0 | 50.8 ± 10.8 | ||
| Lesion, n (%) | 0.061a | <0.001a | ||||
| Nasopharynx | 211 (47.8%) | 231 (52.5%) | 187 (42.4%) | 255 (58.0%) | ||
| Oral cavity | 24 (5.4%) | 21 (4.8%) | 31 (7.0%) | 14 (3.2%) | ||
| Oropharynx | 91 (20.6%) | 90 (20.5%) | 100 (22.7%) | 81 (18.4%) | ||
| Hypopharynx | 88 (20.0%) | 59 (13.4%) | 89 (20.2%) | 58 (13.2%) | ||
| Larynx | 27 (6.1%) | 39 (8.9%) | 34 (7.7%) | 32 (7.3%) | ||
| Sex, n (%) | 0.988a | 0.988a | ||||
| Female | 76 (17.2%) | 76 (17.3%) | 76 (17.2%) | 76 (17.3%) | ||
| Male | 365 (82.8%) | 364 (82.7%) | 365 (82.8%) | 364 (82.7%) | ||
| T‐Stage, n (%) | 0.029a | 0.014a | ||||
| T2/1 | 206 (46.7%) | 238 (54.1%) | 204 (46.3%) | 240 (54.5%) | ||
| T4/3 | 235 (53.3%) | 202 (45.9%) | 237 (53.7%) | 200 (45.5%) | ||
| N‐Stage, n (%) | 0.212a | 0.040a | ||||
| N1/0 | 221 (50.1%) | 239 (54.3%) | 215 (48.8%) | 245 (55.7%) | ||
| N3/2 | 220 (49.9%) | 201 (45.7%) | 226 (51.2%) | 195 (44.3%) | ||
| Chemotherapy, n (%) | 0.774a | 0.626a | ||||
| No | 59 (13.4%) | 56 (12.7%) | 60 (13.6%) | 55 (12.5%) | ||
| Yes | 382 (86.6%) | 384 (87.3%) | 381 (86.4%) | 385 (87.5%) | ||
| PET study, n (%) | 0.628a | 0.767a | ||||
| No | 64 (14.5%) | 69 (15.7%) | 65 (14.7%) | 68 (15.5%) | ||
| Yes | 377 (85.5%) | 371 (84.3%) | 376 (85.3%) | 372 (84.5%) | ||
| Smoking, n (%) | 0.070a | 0.811a | ||||
| No | 133 (30.2%) | 158 (35.9%) | 144 (32.7%) | 147 (33.4%) | ||
| Yes | 308 (67.3%) | 282 (64.1%) | 297 (67.3%) | 293 (66.6%) | ||
| Betel Quid, n (%) | 0.653a | 0.185a | ||||
| No | 253 (57.4%) | 259 (58.9%) | 266 (60.3%) | 246 (55.9%) | ||
| Yes | 188 (42.6%) | 181 (41.1%) | 175 (39.7%) | 194 (44.1%) | ||
| Alcohol, n (%) | 0.760a | 0.760a | ||||
| No | 232 (52.6%) | 236 (53.6%) | 323 (52.6%) | 236 (53.6%) | ||
| Yes | 209 (47.4%) | 204 (46.4%) | 209 (47.4%) | 204 (46.4%) | ||
| Comorbidity, n (%) | <0.001b | 0.264 | ||||
| No | 291 (66.0%) | 210 (47.7%) | 259 (58.7%) | 242 (55.0%) | ||
| Yes | 150 (34.0%) | 230 (52.3%) | 182 (41.3%) | 198 (45.0%) | ||
SAT, subcutaneous fat tissue; SM, skeletal muscle; BMI, body mass index; EQD2 Gy, equivalent dose in 2‐Gy fractions; Gy, gray; PET, positron emission tomography; Index: area/height/height.
a
Chi‐square test.
b
anova.